The exponential proliferation of the number of associations, clubs and other groups that distribute cannabis among their members and create new spaces for socialising, has surprised even the most optimistic advocates of more reasonable drug policies. In a short time, and in spite of those in government, civil society has provided a response to a problem that realpolitik has been unable to tackle.
It is time that policymakers, law enforcement, professionals and other parties involved combine their efforts to work towards the implementation of a transparent cannabis chain that is organised in a responsible and professional manner.
International tensions over Uruguay’s decision to regulate the cannabis market reached new levels when Raymond Yans, president of the International Narcotics Control Board (INCB), accused Uruguay of negligence with regard to public health concerns, deliberately blocking dialogue attempts and having a "pirate attitude" towards the UN conventions. President Mujica reacted angrily, declaring that someone should "tell that guy to stop lying," while Milton Romani, ambassador to the Organisation of American States (OAS), said that Yans "should consider resigning because this is not how you treat sovereign states."
Barely a week after an opinion poll showed that 65% of the Dutch are in favour of regulating cannabis production just as in Uruguay, the minister of Justice and Security of The Netherlands, Ivo Opstelten, told parliament that he will not allow regulated cannabis cultivation to supply the coffeeshops in the country. Two in three large municipal councils back regulated cannabis cultivation, but the minister will probably not allow a single one of the 25 proposals to experiment with regulated cultivation that have been submitted.
The Beckley report, Licensing and Regulation of the Cannabis Market in England and Wales: Towards a Cost-Benefit Analysis, grasps of the economic consequences of a regulated market, as opposed to the current prohibitionist model. This is essential for evaluating the impacts of possible drug policy reform. The report outlines the factors which must be included in further cost-benefit analyses. The report costed 60.000 pounds and 3 years to create. Reliable data was often lacking and more evidence is needed.